Blood-based biomarkers for the diagnosis and monitoring of gliomas DOI Open Access

Marcus Zachariah,

João Paulo Oliveira–Costa, Bob S. Carter

et al.

Neuro-Oncology, Journal Year: 2018, Volume and Issue: 20(9), P. 1155 - 1161

Published: May 6, 2018

Monitoring patient response to treatment is challenging for most cancers, but it particularly difficult in glioblastoma multiform, the common and aggressive form of malignant brain tumor. These tumors exhibit a high degree heterogeneity which may not be reflected biopsy. To determine if current standard care effective, glioma patients are monitored using MRI or CT scans, an effective sometimes misleading approach due phenomenon pseudoprogression. As such, there incredible need minimally invasive "liquid biopsy" assist molecularly characterizing while also aiding identification true progression glioblastoma. This review details status potential impact circulating tumor cells, extracellular vesicles, ctDNA, ctRNA, putative biomarkers found blood patients. mutation-based therapy becomes more prevalent gliomas, blood-based analyses offer non-invasive method identifying mutations. The ability obtain serial biopsies" will provide unique opportunities study evolution mechanisms resistance monitor mutational changes therapy.

Language: Английский

RNA delivery by extracellular vesicles in mammalian cells and its applications DOI Open Access
Killian P. O’Brien, Koen Breyne, Stefano Ughetto

et al.

Nature Reviews Molecular Cell Biology, Journal Year: 2020, Volume and Issue: 21(10), P. 585 - 606

Published: May 26, 2020

Language: Английский

Citations

1434
Circulating Extracellular Vesicles in Human Disease DOI
Ravi V. Shah, Tushar Patel, Jane E. Freedman

et al.

New England Journal of Medicine, Journal Year: 2018, Volume and Issue: 379(10), P. 958 - 966

Published: Sept. 5, 2018

Interview with Dr. Tushar Patel on the role of extracellular vesicles in physiologic function and as potential biomarkers for disease. (08:09)Download Circulating vesicles, which are produced by normal diseased tissues released into body fluids, can be markers disease processes perhaps even tools to deliver new therapies.

Language: Английский

Citations

649
An estimate of the total number of true human miRNAs DOI Creative Commons
Julia Alles, Tobias Fehlmann, Ulrike Fischer

et al.

Nucleic Acids Research, Journal Year: 2019, Volume and Issue: 47(7), P. 3353 - 3364

Published: Feb. 7, 2019

While the number of human miRNA candidates continuously increases, only a few them are completely characterized and experimentally validated. Toward determining total true miRNAs, we employed combined in silico high- experimental low-throughput validation strategy. We collected 28 866 small RNA sequencing data sets containing 363.7 billion reads excluded falsely annotated low quality data. Our high-throughput analysis identified 65% 24 127 mature as likely false-positives. Using northern blotting, validated miRBase entries novel candidates. By exogenous overexpression 108 precursors that encode 205 confirmed 68.5% with confirmation rate going up to 94.4% for high-confidence 18.3% Analyzing endogenous verified expression 8 miRNAs 12 different cell lines. In total, extrapolated 2300 1115 which currently V22. The will contribute revising targetomes hypothesized by utilizing miRNAs.

Language: Английский

Citations

499
Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis DOI
Gabriele De Rubis,

Sabna Rajeev Krishnan,

Mary Bebawy

et al.

Trends in Pharmacological Sciences, Journal Year: 2019, Volume and Issue: 40(3), P. 172 - 186

Published: Feb. 5, 2019

Language: Английский

Citations

464
Prognostic and Predictive Biomarkers in Gliomas DOI Open Access
Paulina Śledzińska, Marek Bebyn, Jacek Furtak

et al.

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(19), P. 10373 - 10373

Published: Sept. 26, 2021

Gliomas are the most common central nervous system tumors. New technologies, including genetic research and advanced statistical methods, revolutionize therapeutic approach to patient reveal new points of treatment options. Moreover, 2021 World Health Organization Classification Tumors Central Nervous System has fundamentally changed classification gliomas incorporated many molecular biomarkers. Given rapid progress in neuro-oncology, here we compile latest on prognostic predictive biomarkers gliomas. In adult patients, IDH mutations positive markers have greatest significance. However, CDKN2A deletion, IDH-mutant astrocytomas, is a marker highest malignancy grade. presence TERT promoter mutations, EGFR alterations, or combination chromosome 7 gain 10 loss upgrade IDH-wildtype astrocytoma glioblastoma. pediatric H3F3A alterations important which predict worse outcome. MGMT methylation clinical significance predicting responses temozolomide (TMZ). Conversely, mismatch repair defects cause hypermutation phenotype poor response TMZ. Finally, discussed liquid biopsies, promising diagnostic, prognostic, techniques, but further work needed implement these novel technologies practice.

Language: Английский

Citations

261
Biomarkers as drug development tools: discovery, validation, qualification and use DOI
Virginia B. Kraus

Nature Reviews Rheumatology, Journal Year: 2018, Volume and Issue: 14(6), P. 354 - 362

Published: May 14, 2018

Language: Английский

Citations

183
Liquid biopsy in gliomas: A RANO review and proposals for clinical applications DOI Open Access
Riccardo Soffietti, Chetan Bettegowda, Ingo K. Mellinghoff

et al.

Neuro-Oncology, Journal Year: 2022, Volume and Issue: 24(6), P. 855 - 871

Published: Jan. 5, 2022

There is an extensive literature highlighting the utility of blood-based liquid biopsies in several extracranial tumors for diagnosis and monitoring.The RANO (Response Assessment Neuro-Oncology) group developed a multidisciplinary international Task Force to review English on biopsy gliomas focusing most frequently used techniques, that circulating tumor DNA, cells, extracellular vesicles blood CSF.ctDNA has higher sensitivity capacity represent spatial temporal heterogeneity comparison cells. Exosomes have advantages cross intact blood-brain barrier carry also RNA, miRNA, proteins. Several clinical applications are suggested: establish when tissue not available, monitor residual disease after surgery, distinguish progression from pseudoprogression, predict outcome.There need standardization biofluid collection, choice analyte, detection strategies along with rigorous testing future trials validate findings enable entry into practice.

Language: Английский

Citations

82
microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)—Recent Literature Review DOI Open Access
Marianna Makowska, Beata Smolarz, Hanna Romanowicz

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(4), P. 3521 - 3521

Published: Feb. 9, 2023

Glioblastoma multiforme (GBM) is the most common, malignant, poorly promising primary brain tumor. GBM characterized by an infiltrating growth nature, abundant vascularization, and a rapid aggressive clinical course. For many years, standard treatment of gliomas has invariably been surgical supported radio- chemotherapy. Due to location significant resistance conventional therapies, prognosis glioblastoma patients very poor cure rate low. The search for new therapy targets effective therapeutic tools cancer current challenge medicine science. microRNAs (miRNAs) play key role in cellular processes, such as growth, differentiation, cell division, apoptosis, signaling. Their discovery was breakthrough diagnosis diseases. Understanding structure miRNAs may contribute understanding mechanisms regulation dependent on miRNA pathogenesis diseases underlying these short non-coding RNAs, including glial tumors. This paper provides detailed review latest reports relationship between changes expression individual formation development gliomas. use this also discussed.

Language: Английский

Citations

61
miRNAs role in glioblastoma pathogenesis and targeted therapy: Signaling pathways interplay DOI
Shereen Saeid Elshaer, Ahmed I. Abulsoud, Doaa Fathi

et al.

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 246, P. 154511 - 154511

Published: May 9, 2023

Language: Английский

Citations

58
Liquid biopsy in cancer current: status, challenges and future prospects DOI Creative Commons
Liwei Ma, Huiling Guo, Yunxiang Zhao

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Dec. 1, 2024

Cancer has a high mortality rate across the globe, and tissue biopsy remains gold standard for tumor diagnosis due to its level of laboratory standardization, good consistency results, relatively stable samples, accuracy results. However, there are still many limitations drawbacks in application tumor. The emergence liquid provides new ideas early prognosis Compared with biopsy, advantages treatment various types cancer, including non-invasive, quickly so on. Currently, detection received widely attention. It is now undergoing rapid progress, it holds significant potential future applications. Around now, biopsies encompass several components such as circulating cells, DNA, exosomes, microRNA, RNA, platelets, endothelial cells. In addition, advances identification indicators have significantly enhanced possibility utilizing clinical settings. this review, we will discuss application, challenges some common tumors from perspective diverse systems tumors, look forward development prospects field cancer treatment.

Language: Английский

Citations

57